EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Aurora kinase B relocation blocker LXY18 triggers mitotic catastrophe selectively in malignant cells

Julia Kalashova, Chenglu Yang, Hongmei Li, Yan Long, Duo Yu, Ting Zhang, Xumei Liu, Namrta Choudhry, Qiong Shi, Thaddeus D Allen iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0293283 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Julia Kalashova und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Discovery Oncology, Chengdu Anticancer Bioscience, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Aurora Kinase A, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The J. Michael Bishop Institute of Cancer Research receives funding through an endowment from Anticancer Bioscience, a company actively engaged in the commerci….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mitotic regulator, Aurora kinase B (AURKB), is frequently overexpressed in malignancy and is a target for therapeutic intervention. The compound, LXY18, is a potent, orally available small molecule that inhibits the proper localization of AURKB during late mitosis, without affecting its kinase activity. In this study, we demonstrate that LXY18 elicits apoptosis in cancer cells derived from various indications, but not in non-transformed cell lines. The apoptosis is p53-independent, triggered by a prolonged mitotic arrest and occurs predominantly in mitosis. Some additional cells succumb post-mitotic slippage. We also demonstrate that cancer cell lines refractory to AURKB kinase inhibitors are sensitive to LXY18. The mitotic proteins MKLP2, NEK6, NEK7 and NEK9 are known regulators of AURKB localization during the onset of anaphase. LXY18 fails to inhibit the catalytic activity of these AURKB localization factors. Overall, our findings suggest a novel activity for LXY18 that produces a prolonged mitotic arrest and lethality in cancer cells, leaving non-transformed cells healthy. This new activity suggests that the compound may be a promising drug candidate for cancer treatment and that it can also be used as a tool compound to further dissect the regulatory network controlling AURKB localization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aurora Kinase ANeoplasmsHumansAurora Kinase BCell DeathMitosisNIMA-Related Kinases

Substanzen

Aurora Kinase BAurora Kinase ANEK6 protein, humanNIMA-Related KinasesNEK9 protein, human

Autor:innen und Institutionen

  • Division of Discovery Oncology, Chengdu Anticancer Bioscience, Chengdu, Sichuan, China.
  • Department of Basic Cancer Research, J. Michael Bishop Institute of Cancer Research, Chengdu, Sichuan, China.

ORCID-Profile: Thaddeus D Allen

Förderung

  • The J. Michael Bishop Institute of Cancer Research receives funding through an endowment from Anticancer Bioscience, a company actively engaged in the commerci…

Zitieren

APA

Kalashova, J., Yang, C., Li, H., Long, Y., Yu, D., Zhang, T., Liu, X., Choudhry, N., Shi, Q., & Allen, T. D. (2023). The Aurora kinase B relocation blocker LXY18 triggers mitotic catastrophe selectively in malignant cells. PLOS ONE. https://doi.org/10.1371/journal.pone.0293283

Vancouver

Kalashova J, Yang C, Li H, Long Y, Yu D, Zhang T, et al. The Aurora kinase B relocation blocker LXY18 triggers mitotic catastrophe selectively in malignant cells. PLOS ONE. 2023. doi:10.1371/journal.pone.0293283

BibTeX
@article{Kalashova2023,
  author = {Kalashova, Julia and Yang, Chenglu and Li, Hongmei and Long, Yan and Yu, Duo and Zhang, Ting and Liu, Xumei and Choudhry, Namrta and Shi, Qiong and Allen, Thaddeus D},
  title = {The Aurora kinase B relocation blocker LXY18 triggers mitotic catastrophe selectively in malignant cells},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0293283}
}
Kostenlos starten →